Did you mean aromatase inhibitor?
Displaying drugs 101 - 125 of 2437 in total
Isoflurophate
An irreversible cholinesterase inhibitor with actions similar to those of echothiophate. It is a powerful miotic used mainly in the treatment of glaucoma. Its vapor is highly toxic and it is recommended that only solutions in arachis oil be used therapeutically. (From Martindale, The Extra Pharmacopoeia, 29th ed, p1330)
Approved
Investigational
Withdrawn
Matched Categories: … Enzyme Inhibitors ... Protease Inhibitors ... Cholinesterase Inhibitors …
Rilpivirine
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance...
Approved
Matched Categories: … BCRP/ABCG2 Inhibitors ... Enzyme Inhibitors ... OATP1B3 inhibitors ... P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors …
Cannabidiol
Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... UGT1A9 Inhibitors ... UGT2B7 Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors …
Pacritinib
Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow. The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. While some patients may remain asymptomatic, typical symptoms of MF...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... OCT1 inhibitors ... OCT2 Inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors …
Voriconazole
Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase...
Approved
Matched Categories: … Enzyme Inhibitors ... 14-alpha Demethylase Inhibitors ... Steroid Synthesis Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Etoricoxib
Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic...
Approved
Investigational
Matched Categories: … COX-2 Inhibitors ... Enzyme Inhibitors ... Cyclooxygenase Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Duloxetine
Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a...
Approved
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Norepinephrine Uptake Inhibitors …
Afatinib
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations...
Approved
Matched Categories: … Enzyme Inhibitors ... BCRP/ABCG2 Inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors ... Tyrosine Kinase Inhibitors …
Clofazimine
Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as dapsone, for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors …
Ropeginterferon alfa-2b
Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), characterized by increased hematocrit and platelet/leukocyte counts, an increased risk for hemorrhage and thromboembolic events, and a long-term propensity for myelofibrosis and leukemia.[A242000, A242005] Interferon alfa-2b has been used for decades to treat PV but requires frequent dosing...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) …
Acalabrutinib
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others.
As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic...
Approved
Investigational
Matched Description: … a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors …
Matched Categories: … Enzyme Inhibitors ... Protein Kinase Inhibitors ... Tyrosine Kinase Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors …
Matched Categories: … Enzyme Inhibitors ... Protein Kinase Inhibitors ... Tyrosine Kinase Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors …
Pyrimethamine
One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.
Approved
Investigational
Vet approved
Matched Categories: … MATE inhibitors ... Enzyme Inhibitors ... MATE 1 Inhibitors ... MATE 2 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors …
Nicotinamide
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP2E1 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Edoxaban
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated...
Approved
Matched Categories: … Enzyme Inhibitors ... Factor Xa Inhibitors ... Protease Inhibitors ... Direct factor Xa inhibitors ... Serine Protease Inhibitors …
Clotrimazole
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s . Clotrimazole falls under the imidazole category of azole antifungals, possessing broad-spectrum antimycotic activity . It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As...
Approved
Vet approved
Matched Categories: … Enzyme Inhibitors ... BSEP/ABCB11 Inhibitors ... P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Steroid Synthesis Inhibitors …
Topotecan
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Approved
Investigational
Matched Categories: … MATE inhibitors ... Enzyme Inhibitors ... MATE 1 Inhibitors ... Topoisomerase Inhibitors ... Topoisomerase I Inhibitors …
Vismodegib
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling pathway, vismodegib...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... Hedgehog pathway inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors …
Adagrasib
Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate...
Approved
Investigational
Matched Description: … [A254941] However, the development of KRAS inhibitors has been challenging due to their high affinity …
Matched Categories: … RAS GTPase Inhibitors ... P-glycoprotein inhibitors ... Immune Checkpoint Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Matched Categories: … RAS GTPase Inhibitors ... P-glycoprotein inhibitors ... Immune Checkpoint Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Pirfenidone
Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Chloramphenicol
An antibiotic first isolated from cultures of Streptomyces venezuelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)...
Approved
Vet approved
Withdrawn
Matched Categories: … Enzyme Inhibitors ... OAT1/SLC22A6 inhibitors ... Protein Synthesis Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors …
Trastuzumab
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal...
Approved
Investigational
Matched Categories: … HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors …
Zimelidine
Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving many organs including skin exanthema, flu-like symptoms, arthralgias, and sometimes eosinophilia. Additionally, zimelidine was charged to cause an increase in suicidal ideation...
Approved
Withdrawn
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Neurotransmitter Uptake Inhibitors …
Grapefruit
Grapefruit allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Repotrectinib
Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the ROS1 gene. ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... MATE inhibitors ... MATE 2 Inhibitors ... UGT1A1 Inhibitors ... P-glycoprotein inhibitors …
Erythromycin
Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those...
Approved
Investigational
Vet approved
Matched Categories: … Enzyme Inhibitors ... BSEP/ABCB11 Inhibitors ... OATP1B3 inhibitors ... P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors …
Displaying drugs 101 - 125 of 2437 in total